Literature DB >> 27496656

Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia.

Catherine M Bulka1, Maxim A Terekhov, Barbara J Martin, Roger R Dmochowski, Rachel M Hayes, Jesse M Ehrenfeld.   

Abstract

BACKGROUND: Residual postoperative paralysis from nondepolarizing neuromuscular blocking agents (NMBAs) is a known problem. This paralysis has been associated with impaired respiratory function, but the clinical significance remains unclear. The aims of this analysis were two-fold: (1) to investigate if intermediate-acting NMBA use during surgery is associated with postoperative pneumonia and (2) to investigate if nonreversal of NMBAs is associated with postoperative pneumonia.
METHODS: Surgical cases (n = 13,100) from the Vanderbilt University Medical Center National Surgical Quality Improvement Program database who received general anesthesia were included. The authors compared 1,455 surgical cases who received an intermediate-acting nondepolarizing NMBA to 1,455 propensity score-matched cases who did not and 1,320 surgical cases who received an NMBA and reversal with neostigmine to 1,320 propensity score-matched cases who did not receive reversal. Postoperative pneumonia incidence rate ratios (IRRs) and bootstrapped 95% CIs were calculated.
RESULTS: Patients receiving an NMBA had a higher absolute incidence rate of postoperative pneumonia (9.00 vs. 5.22 per 10,000 person-days at risk), and the IRR was statistically significant (1.79; 95% bootstrapped CI, 1.08 to 3.07). Among surgical cases who received an NMBA, cases who were not reversed were 2.26 times as likely to develop pneumonia after surgery compared to cases who received reversal with neostigmine (IRR, 2.26; 95% bootstrapped CI, 1.65 to 3.03).
CONCLUSIONS: Intraoperative use of intermediate nondepolarizing NMBAs is associated with developing pneumonia after surgery. Among patients who receive these agents, nonreversal is associated with an increased risk of postoperative pneumonia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27496656     DOI: 10.1097/ALN.0000000000001279

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  28 in total

1.  Improved Compliance With Anesthesia Quality Measures After Implementation of Automated Monthly Feedback.

Authors:  Patrick J McCormick; Cindy Yeoh; Raquel M Vicario-Feliciano; Kaitlin Ervin; Kay See Tan; Gloria Yang; Meghana Mehta; Luis Tollinche
Journal:  J Oncol Pract       Date:  2019-05-20       Impact factor: 3.840

Review 2.  Reversal of neuromuscular block.

Authors:  J M Hunter
Journal:  BJA Educ       Date:  2020-07-01

3.  Neuromuscular Block and Blocking Agents in 2018.

Authors:  Christoph Unterbuchner
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-04-01

4.  Sugammadex in the management of myasthenic patients undergoing surgery: beyond expectations.

Authors:  Michele Carron; Alessandro De Cassai; Federico Linassi
Journal:  Ann Transl Med       Date:  2019-12

5.  Survey of neuromuscular monitoring and assessment of postoperative residual neuromuscular block in a postoperative anaesthetic care unit.

Authors:  Xu Feng Lin; Christine Yoke Kuen Yong; May Un Sam Mok; Poopalalingam Ruban; Patrick Wong
Journal:  Singapore Med J       Date:  2019-09-19       Impact factor: 1.858

6.  Preliminary Indications for the Use of Sugammadex After Its Addition to a Formulary at a Tertiary Care Children's Hospital.

Authors:  N'Diris Barry; Joshua C Uffman; Dmitry Tumin; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

7.  Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis.

Authors:  Sachin Kheterpal; Michelle T Vaughn; Timur Z Dubovoy; Nirav J Shah; Lori D Bash; Douglas A Colquhoun; Amy M Shanks; Michael R Mathis; Roy G Soto; Amit Bardia; Karsten Bartels; Patrick J McCormick; Robert B Schonberger; Leif Saager
Journal:  Anesthesiology       Date:  2020-06       Impact factor: 7.892

8.  ED50 of remifentanil for providing excellent intubating conditions when co-administered with a single standard dose of propofol without the use of muscle relaxants in children: dose-finding clinical trial.

Authors:  Andre Hideo Ono; Thiago Rocha Moura; Cátia Sousa Govêia; Gabriel Magalhães Nunes Guimarães; Luís Cláudio de Araújo Ladeira; Helga Bezerra Gomes da Silva
Journal:  J Anesth       Date:  2018-05-04       Impact factor: 2.078

9.  Comparison of intubating conditions after induction with propofol and remifentanil or sufentanil : Randomized controlled REMIDENT trial for surgical tooth extraction.

Authors:  A Dolsan; L Bruneteau; C Roche; F Ferré; F Labaste; A Sommet; J-M Conil; V Minville
Journal:  Anaesthesist       Date:  2020-02-28       Impact factor: 1.041

Review 10.  [Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].

Authors:  C Unterbuchner; K Ehehalt; B Graf
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.